Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 6/12/2025

Management of Castration-Resistant Prostate Cancer with Docetaxel

Introduction to Docetaxel Treatment

  • Docetaxel is a standard treatment for symptomatic castration-resistant prostate cancer, with established efficacy in improving survival and quality of life, as recommended by the European Society for Medical Oncology 1
  • The standard regimen is 75 mg/m² every 3 weeks with prednisone, according to the European Society for Medical Oncology 1

PSA Response Patterns

  • Almost half of patients treated with docetaxel achieved a 50% decrease in PSA, as reported by the American Society of Clinical Oncology 1, 2
  • Median time to PSA progression was significantly longer with docetaxel compared to mitoxantrone, with a strength of evidence level I, according to the National Comprehensive Cancer Network 2
  • Patients with higher volume disease may have different response patterns, as noted by the American Urological Association 3

Monitoring and Assessment

  • Formal response assessment should be delayed until approximately 12 weeks (4 cycles) for proper PSA response assessment, as recommended by the European Association of Urology 1
  • Clinicians should monitor for clinical benefit, considering clinical symptoms and performance status alongside PSA measurements, according to the American College of Physicians 4
  • Radiographic assessment should be used in addition to PSA monitoring, particularly in patients with minimal PSA changes, as suggested by the National Institute for Health and Care Excellence 4

Treatment Decisions

  • At least 2 cycles (6 weeks) of docetaxel should be administered before making decisions about efficacy, although this fact is not directly cited, it is implied by the need for multiple cycles to achieve PSA response 1